You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • Reference number: TA268
  • Published:  12 December 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Melanoma (stage III or IV) - ipilimumab: Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research

Melanoma (stage III or IV) - ipilimumab: 
Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research Melanoma (stage III or IV) - ipilimumab: Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research
02 November 2012
(253.12 Kb 13 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 31 October 2012

Back to top